Lina Hassoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lina Hassoun has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Leptich
Clinical Study Unit, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany
1 shared publication - Katja Thomas
Center of Clinical Neuroscience, Department of Neurology, Carl Gustav Carus University Hospital, University of Technology Dresden, Fetscherstr. 74, 01307, Dresden, Germany
1 shared publication - Raimar Kern
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
1 shared publication Sigbert Jahn
Medical Affairs, Genzyme GmbH, Neu-Isenburg, Germany
1 shared publication- Tjalf Ziemssen
Universitätsklinikum Carl Gustav Carus
1 shared publication - Ulrich Engelmann
Medical Affairs, Genzyme GmbH, Neu-Isenburg, Germany
1 shared publication
Latest Publications
- Open Access
- 19 July 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 109
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clinical trials studies, alemtuzumab administered in two annual courses, had superior efficacy as compared to subcutaneous interferon beta-1a, and durable efficacy over 5 years in an extension study with a manageable safety profile in RRMS patients. Data on the utilization and the outcomes of alemtuzumab under clinical practice conditions are limited. Here we describe the rationale, design and methods of the TREAT-MS study (non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS). TREAT-MS is a prospective, multicenter, non-interventional, long-term study to collect data on safety, effectiveness, quality of life, cognition and other aspects from 3200 RRMS patients treated with alemtuzumab under the conditions of real-world clinical practice in Germany. As non-interventional trial in Germany.
- 19 July 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 109
Open AccessRationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clinical trials studies, alemtuzumab administered in two annual courses, had superior efficacy as compared to subcutaneous interferon beta-1a, and durable efficacy over 5 years in an extension study with a manageable safety profile in RRMS patients. Data on the utilization and the outcomes of alemtuzumab under clinical practice conditions are limited. Here we describe the rationale, design and methods of the TREAT-MS study (non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS). TREAT-MS is a prospective, multicenter, non-interventional, long-term study to collect data on safety, effectiveness, quality of life, cognition and other aspects from 3200 RRMS patients treated with alemtuzumab under the conditions of real-world clinical practice in Germany. As non-interventional trial in Germany.